Indefinite Delivery Contract HHSO100201100034C

Award Date 9/15/11
Last Date to Order 4/25/22
Federal Contract Vehicle
Pricing Type
Cost Plus Fixed Fee
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian federal agency, to Glaxosmithkline, LLC, a pharmaceutical company, to provide a portfolio of new antibacterial drugs for hospital and biothreat pathogens. The single-award IDC has a ceiling value of $255,851,502.87 and a period of performance through September 30, 2029. The contract aims to procure a range of pharmaceutical products and services from...
This indefinite delivery contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency within the U.S. Department of Health and Human Services (HHS). The IDC has a ceiling value of $44,440,563.00 and a period of performance from September 2, 2015 to September 30, 2023. The primary purpose of this IDC is to support the development of Regeneron's anti-Ebola antibody therapeutics program. Regeneron Pharmaceuticals Inc., a for-profit...
This Indefinite Delivery Contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Ansun Biopharma, Inc. The contract's purpose is to procure a broad-spectrum antiviral therapeutic for the treatment of influenza A and B virus infections. The total ceiling value of the contract is $19,112,357.63, and the period of performance runs from the award date of September 29, 2012 through the ultimate completion date of February 28, 2014. This...
This federal Indefinite Delivery Contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to the prime contractor Advanced Technology International (ATI), a public service nonprofit organization. The contract has a ceiling value of $10 billion and a period of performance through September 2033. The contract aims to acquire innovative technologies and rapid development/response...
This Indefinite Delivery Contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Emory University, a private research university. The contract has a ceiling value of $146,300,000 and a period of performance through July 2031. The purpose of this IDC is to provide NIAID with the capability to develop, refine, and employ small animal models, non-human primate models, animal...
This Indefinite Delivery Contract (IDC) was awarded by the Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response, to Glaxosmithkline, LLC, a foreign-owned pharmaceutical company. The contract has a ceiling value of $78,310,394.13 and a period of performance ending on July 22, 2025. The purpose of this IDC is to provide a broad range of pharmaceutical products and medical countermeasures to various federal agencies, including influenza...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a subsidiary of the Illinois Institute of Technology. The contract has a ceiling value of $146.3 million and a period of performance through July 2031. The purpose of this IDC is to provide NIAID with a range of preclinical research services related to the development and...
The federal contract IDV award, with an ID of 75N93024D00022, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services (HHS). This single-award Indefinite Delivery Contract, potentially valued up to $146,300,000, is for pre-clinical models of infectious diseases under task areas A, B, and C. The prime contractor, Texas Biomedical Research Institute, will provide a range of services including developing...
This Indefinite Delivery Contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian federal agency, to Southern Research Institute, a non-profit research organization. The contract has a ceiling value of $5,000,000 and a performance period ending on July 13, 2012. The contract aims to procure "OTHER SPECIAL STUDIES AND ANALYSES" for ASPR. Two task orders have been issued under this IDC to date, valued at $244,710 and $240,723...
The federal contract IDV award is for an Indefinite Delivery Contract with a ceiling value of $146,300,000 awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services. The contract is focused on providing pre-clinical models of infectious diseases to support research, development, and evaluation of medical countermeasures such as therapeutics, vaccines, and diagnostics. The contract has a single award to...

The provided information describes an Indefinite Delivery Contract (IDC) awarded by the Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response, to the prime contractor Elusys Therapeutics Inc. The contract has a total ceiling value of $69,586,152.55 and a period of performance ending on April 25, 2022.

The contract is focused on Research and Development Facilities, with the prime contractor providing a range of biomedical products and services, including "ANTHIM LETTER CONTRACT", "FOR OTHER FUNCTIONS", "BIOMEDICAL (ADVANCED)", and "BIOMEDICAL (BASIC)". The contractor has a history of delivering both definitive contracts and delivery orders, and has expanded its customer base over time to include not only the Department of Defense (DOD), but also HHS and the National Institutes of Health (NIH). The parent company of the prime contractor, Nighthawk Biosciences, Inc. (doing business as Heat Biologics), is a biopharmaceutical company focused on developing therapies to activate the immune system against cancer and other diseases, and has received multiple federal grants to support its research and development efforts.

Generated 8/16/24, 9:28 AM